Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 650

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Diagnosis and treatment of Parkinson disease: molecules to medicine

Open access
Savitt, J. M.·2006·Journal of Clinical Investigation

Abstract

Parkinson disease (PD) is a chronic, progressive neurodegenerative disorder that affects at least 1% of people by age 70 (1-3).James Parkinson provided the first detailed description of the disease in his 1817 monograph "An Essay on the Shaking Palsy."In the latter part of the nineteenth century, Charcot further refined the description of this disorder and identified the cardinal clinical features of PD including rest tremor, rigidity, balance impairment, and slowness of movement (reviewed in ref. 4).An early clue to the pathology of the disease came from Brissaud, who speculated that damage in the substantia nigra (SN) might lead to PD (5, 6).Eosinophilic inclusions (Lewy bodies) later were identified in the brains of PD patients (7) and, along with abnormalities in the SN, became a recognized pathologic marker of the disease (8).A major advance in the understanding of PD came when dopamine deficiency was discovered in the corpus striatum and SN of brains taken from patients (9).Later studies demonstrated the connection between the SN and the striatum, thus suggesting that dopaminergic cell loss in the SN directly leads to dopaminergic deficiency in the striatum (10).The determination that PD is a disease of dopamine loss led to the development of ratio-nal therapies aimed at correcting this deficiency (11).After some initial uncertainty, the dopamine precursor levodopa proved to be a powerful PD treatment (12).Subsequent advances in therapy included combining levodopa with a peripheral decarboxylase inhibitor, such as carbidopa or benserazide (13, 14).This combination significantly reduced the nausea and vomiting associated with levodopa therapy and allowed a greater proportion of levodopa to enter the brain.Similarly, catechol-O-methyltransferase (COMT) inhibitors, which prolong the half-life of levodopa and dopamine were found to enhance the effect of a given levodopa dose (15-17).In addition to increasing the level of dopamine precursors, the focus of therapeutic design was also on limiting the breakdown of endogenous dopamine.The monoamine oxidase type B (MAO-B) inhibitor selegiline works in this fashion and provides symptomatic benefit (18).Finally, the development of dopamine agonists that directly stimulate postsynaptic dopamine receptors, thus bypassing dopamine synthesis completely, further illustrates how novel therapies can be borne from knowledge of pathology (19,20).Surgical therapies that reduce tremor and rigidity in PD patients were used prior to the advent of levodopa treatment.Meyers pioneered surgical lesioning procedures that targeted symptoms and spared patients from the hemiparesis that resulted from earlier surgical approaches.These procedures largely were abandoned once levodopa therapy became more common (21).Recent advances in the understanding of basal ganglia physiology and the development of new technologies has led to a reemergence of surgical PD therapies in the form of deep brain stimulation (DBS) (22,23).DBS has become increasingly common in patients whose disease is difficult to manage with medical therapy alone.Despite these landmark advances in symptomatic PD therapy, the ability of these treatments to facilitate an acceptable quality of life for the patient wanes with time.This is due to the development of motor complications including wearing-off (the Diagnosis and treatment of Parkinson disease: molecules to medicine

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci29178

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 650

Metadata

Authors
Savitt, J. M.
Venue
Journal of Clinical Investigation
Published
2006-07-03
Volume
116
Issue
7
Pages
1744-1754
ISSN
0021-9738 (ISSN-L)
OpenAlex
W1986118996
Cited by
650
References
15
FWCI
21.96
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnosis and treatment of Parkinson disease: molecules to medicine. https://app.cochat.ai/papers/10.1172/jci29178
The paper
Savitt, J. M. (2006). Diagnosis and treatment of Parkinson disease: molecules to medicine. Journal of Clinical Investigation. https://doi.org/10.1172/jci29178

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.